research ‘Ritlecitinib: unveiling hair regrowth for alopecia areata’
Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.
Search
for
Sort by
Research
600-630 / 1000+ resultsresearch Alopecia areata and ritlecitinib: Unravelling response trajectories
Ritlecitinib is effective for long-term hair regrowth in alopecia areata, especially in females and early treatment.
research Alopecia Universalis in an Elderly Chinese Man Induced by Sacubitril/Alisartan, a Novel Angiotensin Receptor-Neprilysin Inhibitor
An elderly Chinese man lost all his hair after taking a new heart medication.
research 53274 Real-world experience of efficacy and safety of baricitinib in Korean patients with severe alopecia areata
Baricitinib 4 mg is effective and safe for treating severe alopecia areata.
research Study on pharmacokinetics and determination of perospirone in human plasma by HPLC-MS/MS
A reliable method was developed to measure perospirone levels in human plasma for clinical use.
research First reboxetine trial results reported
Finasteride increased hair count and regrowth in men with hair loss but also caused more sexual side effects than placebo.
research Single nucleotide polymorphisms associated with elevated alanine aminotransferase in patients receiving asunaprevir plus daclatasvir combination therapy for chronic hepatitis C
Certain genetic variations are linked to higher liver enzyme levels in patients treated for chronic hepatitis C with specific drugs.
research Increased retinol‐binding protein (RBP) 4 and anti‐RBP4 antibody in alopecia areata
People with alopecia areata have higher levels of RBP4 protein and antibodies against it.
research ATRICHIA WITH PAPULAR LESIONS – A CASE REPORT
No effective treatment exists to stimulate hair growth in atrichia with papular lesions.
research 52709 Patient-Reported Outcomes for Scalp, Eyebrow and Eyelash Hair Loss in Patients with Severe Alopecia Areata Treated with Baricitinib: 152 Week Results from two Phase 3 Clinical Trials
Baricitinib helps long-term hair regrowth in severe alopecia areata patients.
research 34007 Efficacy and safety of baricitinib in adult patients with severe alopecia areata with or without an atopic background from 2 randomized, placebo-controlled, phase 3 trials
Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.
research Finasteride 1 mg in alopecia: sexual dysfunction, suicidal ideation. Providing balanced information to male patients is key.
research Groundnut seed production manual.
Arsenic trioxide effectively treats APL, improving survival rates despite its toxicity.
research Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata
Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.
research Comparative efficacy of oral Janus kinase inhibitors and biologics in adult alopecia areata: A systematic review and Bayesian network meta‐analysis
Baricitinib is the most effective treatment for alopecia areata.
research The neurosteroidogenic enzyme 5α-reductase modulates the role of D1 dopamine receptors in rat sensorimotor gating
5α-reductase affects dopamine receptors linked to sensorimotor gating, which may help understand disorders like schizophrenia.
research Distribution of SALT Scores with Ritlecitinib Treatment up to 24 months from the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia Areata
Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.
research Synthesis and Study of Some 17a-aza-D-homo Steroids as 5α-Reductase Inhibitors
The research found that compound 6, a newly created steroid, is more effective at inhibiting 5α-reductase (an enzyme) than current treatments, suggesting it could be a better option for treating urinary tract symptoms in men.
research Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata
Ritlecitinib shows promise for hair regrowth in alopecia areata patients.
research Leflunomide
Leflunomide is effective for rheumatoid arthritis but has significant side effects.
research Raltegravir-Induced Alopecia in an HIV+ Patient
Raltegravir may cause hair loss in some patients.
research Cyproterone acetate and risk of meningioma: a nationwide cohort study
Taking high doses of Cyproterone acetate significantly increases the risk of meningioma in females.
research Autoimmune polyendocrine syndrome type 1: an Italian survey on 158 patients
APS-1 in Italy shows diverse AIRE mutations and various autoimmune issues.
research Finasteride, pharmacogenomics, and suicide risk: a public health concern
research Unraveling Ritlecitinib: an in-depth analysis of JAK3 inhibitor for the treatment of alopecia areata
Ritlecitinib is an effective new treatment for Alopecia Areata.
research Baricitinib as the first systemic treatment for severe alopecia areata
Baricitinib is effective as a treatment for severe hair loss.
research Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.
research JAK Inhibitor Baricitinib in the Treatment of Oral Lichen Planus: A Case Report
Baricitinib may effectively treat oral lichen planus.
research 0282 Effect of systemic immunomodulators on incidence of alopecia areata: A retrospective cohort study
Leflunomide may reduce the risk of alopecia areata, while methotrexate, cyclosporine, and rituximab may increase it.
research Hair analysis for cannabinoids and amphetamines in a psychosis incidence study
Hair analysis for drugs in psychosis patients is unreliable due to varying hair growth rates.